Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2137)	11/26/2000 10:39:07 PM
From: Biomaven	Respond to of 52153

Looking at overall market valuation, the following article is of interest: thestreet.com Comparing the 10-year Treasury yield to the S&P earnings yield is a simple but defensible metric of the market's valuation. It's no longer yelling "Sell!" Peter

To: Biomaven who wrote (2137)	11/26/2000 11:19:18 PM
From: Miljenko Zuanic	Respond to of 52153

<<The big worry is that health care costs are increasingly a giant black hole that will suck up any and all resources that come anywhere vaguely near sucking distance. This is only going to get worse as better and fancier drugs get discovered and organ engineering or xenotransplantation becomes a reality.>> The economic price of any new drug should be partially evaluated by economic benefit it provide. For instance, one day in Mexico hospital does not cost $3-30K. Total medical and health care cost will definitely growth at close to +10% rate for some time, imo. The only way to control this is COMPETITIONS, not GOVERNMENT regulation, again imo. Also, this may be relevant to tread. Message 14884028 Miljenko